Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors

LTX-315 is a first-in-class, 9-mer membranolytic peptide that has shown potent immunomodulatory properties in preclinical models. We conducted a phase I dose-escalating study of intratumoral LTX-315 administration in patients with advanced solid tumors. Thirty-nine patients were enrolled, receiving...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2021-05, Vol.27 (10), p.2755-2763
Hauptverfasser:	Spicer, James, Marabelle, Aurélien, Baurain, Jean-Francois, Jebsen, Nina Louise, Jøssang, Dag Erik, Awada, Ahmad, Kristeleit, Rebecca, Loirat, Delphine, Lazaridis, George, Jungels, Christiane, Brunsvig, Paal, Nicolaisen, Berit, Saunders, Andrew, Patel, Hamina, Galon, Jérôme, Hermitte, Fabienne, Camilio, Ketil André, Mauseth, Brynjar, Sundvold, Vibeke, Sveinbjørnsson, Baldur, Rekdal, Øystein
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Biopsy Disease Management Female Humans Immunohistochemistry Injections, Intralesional Lymphocytes, Tumor-Infiltrating Male Middle Aged Neoplasms - diagnosis Neoplasms - drug therapy Neoplasms - etiology Neoplasms - mortality Oligopeptides - administration & dosage Oligopeptides - adverse effects Oligopeptides - pharmacokinetics T-Lymphocytes - drug effects Tomography, X-Ray Computed Treatment Outcome Tumor Microenvironment - drug effects Tumor Microenvironment - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!